Celgene
| Type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 1986 (1986) |
| Founder | Sol J. Barer |
| Headquarters | Summit, New Jersey, U.S. |
| Key people | Robert J. Hugin (Executive Chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue |  $15.281 billion (2018) |
| Net income | $4.046 billion (2018) |
| Total assets | $35.480 billion (2018) |
| Total equity |  $6.161 billion (2018) |
| Number of employees | 8,852 (2018) |
| Parent | Bristol Myers Squibb |
| Website | www.bms.com |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
For detailed contact information visit location pages below.
Celgene's locations around the world
Clinical Trials sponsored by Celgene
-
CelgeneCelgene CorporationFullførtLymfom | KreftForente stater, Storbritannia
-
Celgene CorporationFullført
-
Celgene CorporationFullførtLav- eller middels-1-risiko myelodysplastisk syndrom (MDS)Forente stater
-
Celgene CorporationAvsluttetTykktarmskreftAustralia, Belgia, Tyskland, Italia, Spania, Sverige
-
Celgene CorporationFullførtMyelodysplastiske syndromerForente stater, Danmark, Australia, Belgia, Tsjekkisk Republikk, Frankrike, Tyskland, Hellas, Italia, Nederland, Den russiske føderasjonen, Spania, Sverige, Sveits, Storbritannia
-
Celgene CorporationFullførtMultippelt myelomIrland, Spania, Australia, Østerrike, Storbritannia
-
Celgene CorporationFullførtSmåcellet lungekreftForente stater
-
Celgene CorporationTilbaketrukketMetastatisk brystkreftForente stater
-
Celgene CorporationFullførtNeoplasmer | UtmattelseForente stater
-
Celgene CorporationFullførtMyelodysplastiske syndromerForente stater